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The control of gene expression is pivotal in biology. It is 
accomplished by a large number of regulators, including 
transcription  factors  (TFs),  that  can  modulate  mRNA 
synthesis by directly interacting with regulatory genome 
sequences.  The  human  genome  contains  about  20,000 
genes and an estimated 1,400 TFs [1]. Although much is 
known about the basic mechanics of transcription, little 
is  known  about  how  TFs  function  collectively  in  the 
context of intricate gene regulatory networks (GRNs) to 
achieve complex biological outputs during development 
and in physiology and disease.
Ideally,  one  would  like  to  comprehensively  map  the 
binding of each TF within the genome and understand 
the effects that such interactions have on its target genes. 
Conversely, for each gene, one would like to know which 
TFs contribute to its expression and in which cells and 
under which circumstances this contribution occurs.
Over the past decade several high-throughput method  o-
l  o  gies  have  been  developed,  standardized  and  imple-
mented to map GRNs, including computational reverse 
engineering  (reviewed  in  [2,3]),  chromatin  immuno-
precipitation (ChIP) combined with microarrays (ChIP-
chip) or next generation sequencing (ChIP-seq) (reviewed 
in [4,5]), and yeast one-hybrid (Y1H) assays (reviewed in 
[6,7]).  Each  of  these  methods  has  inherent  limitations, 
and  therefore  GRNs  might  miss  interactions  (false 
negatives)  and  contain  interactions  that  are  not  ‘bio-
logically  meaningful’  (false  positives;  Table  1).  Deter-
mining the scale of these limitations has proven difficult, 
in  part  because  it  is  challenging  to  define  the  term 
‘biologically  meaningful’.  For  instance,  interactions 
between  genes  and  regulators  are  often  deemed  bio-
logically meaningful only if the expression of the gene 
changes following removal or reduction of the regulator, 
and/or if mutations in the gene and the regulator confer 
similar phenotypes. Here, I discuss methods that are used 
to identify interactions between genes and regulators and 
illustrate different levels of validation that can be used to 
obtain further support for these interactions. In addition, 
I argue that lack of validation does not necessarily signify 
irrelevance  because  validation  assays  each  come  with 
their own caveats, and their interpretation can be further 
complicated  by  mechanisms  such  as  TF  redundancy. 
Instead, results from many assays should be combined to 
generate  increasingly  comprehensive,  high-quality  net-
work models.
Gene regulatory networks
GRNs  are  graph  diagrams  that  depict  interactions 
between genes and their regulators (such as TFs). These 
interactions can indicate a regulatory relationship, and/
or can depict a physical interaction between a TF and a 
genomic DNA region associated with a particular gene. A 
genome-scale  method  used  for  inferring  regulatory 
interactions is to computationally search transcriptomic 
data for correlations between gene and TF expression. 
This reverse engineering approach has been pioneered in 
yeast [8] and has also been applied to mammals [9,10]. 
ChIP starts with a protein and is an example of a TF-
centered (protein-to-DNA) method, whereas Y1H starts 
with a DNA fragment and can be referred to as a gene-
centered (DNA-to-protein) technique (reviewed in [6,7]). 
Both  ChIP  (for  example,  [11-16])  and  Y1H  assays  (for 
example, [17-21]) have been successfully used in various 
systems and have each led to a wealth of data. Impor-
tantly, inferred regulatory relationships are not necessarily 
a  result  of  direct  physical  interactions.  Conversely,  for 
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© 2011 BioMed Central Ltdphysical interactions between TFs and DNA, the regu-
latory consequence (repression or activation) is usually 
not  known.  Therefore,  for  optimal  coverage  and  infor-
mation  content,  both  types  of  approaches  need  to  be 
applied and integrated.
What is ‘biologically meaningful’?
The quality of GRNs depends on the proportion of real 
interactions  that  are  retrieved  and  the  proportion  of 
retrieved interactions that are real. For many scientists, 
interactions identified by high-throughput methods are 
deemed biologically meaningful (real) only if a regulatory 
and/or  functional  consequence  is  demonstrated,  after 
which  the  interaction  is  considered  ‘validated  in  vivo’. 
However, a lack of in vivo validation does not necessarily 
invalidate  an  interaction  because:  (i)  in  vivo  validation 
methods  have  their  own  limitations;  (ii)  a  TF  binding 
event might have been attributed to the wrong gene - for 
instance, when a TF binds an enhancer far from a trans-
cription  start  site;  and  (iii)  biological  safety  nets  that 
buffer the loss of individual TFs can mask the effect of 
genuine DNA-TF interactions on gene expression.
Data quality: false negatives
To  obtain  a  complete  picture  of  gene  regulation,  it  is 
important  to  detect  all  physical  and  regulatory  inter-
actions that occur between genes and TFs. However, it is 
likely  that  the  interaction  networks  that  have  been 
deline  ated  so  far  are  incomplete  because  not  all 
interactions  can  be  detected  by  the  method(s)  used. 
There are several reasons why DNA-TF interactions can 
be missed (false negatives; Table 1). In computationally 
inferred  GRNs,  relationships  can  be  missed  when  the 
required cut-off for correlation was set too high, when 
TFs do not change in expression in accordance with their 
target genes, or when the TF or its target is expressed at 
very low levels, thereby disabling detection of expression 
changes.  With  ChIP,  the  detection  of  interactions 
depends  on  the  expression  level,  concentration  and 
activity of the TF in the cell or tissue sampled, and the 
strength and accessibility of its binding sites (Figure 1). 
With  ChIP-Seq,  precipitated  DNA  frag  ments  are 
sequenced, and bound regions are ‘called’ by compiling 
all the reads that correspond to particular genomic DNA 
regions  into  ‘peaks’.  Subsequently,  cut-offs  are  selected 
somewhat arbitrarily to distinguish bound from unbound 
regions [22]. This will inevitably cause the strongest and/
or  most  well-represented  (robust)  inter  actions  to  be 
considered  at  the  expense  of  weaker  inter  actions  that 
might  just  as  likely  be  biologically  meaning  ful.  Gene-
centered Y1H assays also miss DNA-TF inter  actions. For 
instance,  interactions  with  obligatory  hetero  dimers 
cannot be detected with the current con  figura  tions of the 
assay.  In  addition,  TFs  that  require  post-translational 
modification or a cofactor in order to bind DNA may not 
be  retrieved.  When  cDNA  libraries  are  screened,  low-
abundance TFs have a high likelihood of being missed. 
This disadvantage has been partially alleviated by using 
directed Y1H assays in which TFs are tested one by one 
for their ability to bind to a particular DNA fragment 
[23]. Such clone-based assays, however, depend on clone 
resources  such  as  the  ORFeome  [24,25],  and  TFs  for 
which open reading frame clones are not available will 
obviously not be represented in these assays.
Data quality: false positives
False positives can be incorporated into GRNs and can be 
either technical or biological. Technical false positives are 
interactions that are sporadic in nature and cannot be 
repeated, even with the same assay with which they were 
originally  retrieved.  Obviously,  any  high-throughput 
method should avoid detecting spurious interactions by 
carefully optimizing and evaluating the robustness of the 
assay. Biological false positives are defined as interactions 
Table 1. Overview of commonly used techniques for gene regulatory network mapping and their advantages and 
limitations
Method Characteristics Advantages Limitations
Computational inference 
(reverse engineering)
Infers putative regulatory 
relationships from gene 
expression data
Fast; cheap The interactions predicted could be indirect (they do 
not have to reflect physical interactions); regulators that 
themselves do not change in expression will be missed; 
detection limits of mRNA measurements will affect GRN 
predictions (regulators or genes expressed at low levels will 
be missed)
Chromatin 
immunoprecipitation (ChIP)
Experimentally identifies physical 
interactions between TFs and 
DNA; TF-centered (protein-to-
DNA)
In vivo; can detect TF dimers 
and complexes
Condition-dependent interactions can be missed; needs 
high-quality, highly specific ChIP-grade antibodies; when a 
universal tag is used for immunoprecipitation, TF is usually 
overexpressed; peak calling required
Yeast one-hybrid (Y1H) Experimentally identifies physical 
interactions between DNA and 
TFs; gene-centered (DNA-to-
protein)
Heterologous; condition- 
and context-independent
TFs that require post-translational modifications 
before binding DNA will be missed; not yet suitable for 
heterodimers
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meaningful. In computationally derived GRNs spurious 
edges (regulatory interactions) can arise if both a TF and 
its inferred target are regulated by another TF that itself 
does  not  change  in  expression.  In  ChIP  experiments, 
biological  false  positives  might  be  obtained  when  the 
antibody  is  not  exclusively  specific  for  the  TF  that  is 
being  studied,  or  when  a  TF  is  overexpressed  (for 
instance, from a transgene), and starts binding to lower 
affinity  or  non-specific  sites.  Furthermore,  selecting  a 
threshold that is too low when ‘calling’ interactions from 
a background of non-interacting fragments may result in 
the  inclusion  of  false  interactions.  Y1H  assays  can 
retrieve interactions that do not occur in vivo when a TF 
binding site is available in the context of yeast chromatin 
but not in the organism from which the DNA fragment 
was cloned. TF levels in yeast are controlled by a yeast 
promoter and by the copy number of the TF-expressing 
plasmid,  and  it  is  possible  that  lower  affinity  DNA 
sequences are bound when TF levels are high.
Five levels of validation
There  are  five  conceptual  levels  of  validation  of  inter-
actions between genes and their regulators.
The first level is retesting interactions detected with the 
same experimental approach and reagents to minimize 
technical false positives. This can be done by retesting 
individual interactions, or by performing larger, genome-
scale experiments multiple times. For example, in ChIP 
assays, the DNA regions deemed bound by a TF are often 
confirmed  by  quantitative  PCR  of  the  ChIPped  DNA. 
However, this only confirms that the DNA fragment was 
precipitated; it is not a retest of the ChIP assay itself. In 
Y1H assays, interactions retrieved can be confirmed in 
freshly grown yeast cells containing the ‘DNA bait’, using, 
for instance, a TF-encoding clone [26].
The second level is confirming an interaction with the 
same assay but using different reagents. Computationally 
inferred  regulatory  interactions  can  be  assessed  in  an 
independent dataset, or with a different algorithm. ChIP 
interactions  can  be  confirmed  by  using  multiple  anti-
bodies to the same protein [15,27]. The signal-to-noise 
ratio can also be improved by including control experi-
ments of samples in which the TF is removed or reduced 
[12]. In such experiments, DNA regions that are detected 
by  ChIP  both  in  wild-type  and  TF  mutant  or  RNA 
interference  (RNAi)  samples  can  be  considered  false 
posi  tives, and thresholds can be drawn accordingly. Y1H 
assays  use  two  reporter  genes  that  are  integrated  into 
different locations in the yeast genome, and only inter-
actions  that  result  in  the  activation  of  both  reporters 
should be considered, as they are basically detected twice, 
and therefore confirmed. In addition, independent ‘DNA 
bait’ strains and ‘TF preys’ from different clone resources 
can be used to confirm interactions.
The  third  level  is  detecting  an  interaction  with  a 
different assay of the same type. For instance, to validate 
computationally inferred regulatory interactions one can 
use RNAi of a TF and examine changes in the expression 
of its inferred targets in vivo. This approach has recently 
been  used  for  a  subset  of  regulatory  relationships 
inferred to control the pathogenic response of murine 
dendritic  cells  [10].  Physical  interactions  detected  by 
Y1H assays can be confirmed by ChIP and vice versa. For 
example, we have confirmed multiple Y1H interactions 
in  Caeno  rhabditis  elegans  and  Arabidopsis  thaliana 
Figure 1. The detection of physical interaction between a TF and a target gene depends on various parameters, including the expression 
level or concentration of the TF, the activity of the TF, the affinity of the binding site for the TF and the accessibility of the binding site in 
the context of chromatin. TFBS, transcription binding site.
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Page 3 of 7interactions  by  ChIP  [17,21].  Additional  support  for 
physical inter  actions identified either by Y1H assays or 
by ChIP can be obtained by identifying a putative TF 
binding  site  within  the  DNA  fragment  bound,  either 
using motif prediction algorithms (for example, [28-30]) 
or  by  interrogating  large  TF  binding  site  datasets  (for 
example, [31-34]). In Y1H assays, the putative site can be 
deleted and inter  actions with the mutant fragment can 
be examined. Loss of the DNA-TF interaction with the 
mutant  fragment  would  confirm  that  the  selected 
binding site is indeed correct [35].
The fourth level is observing an interaction in a differ-
ent type of assay, that is, a regulatory interaction is con-
firmed by a physical interaction or vice versa. An example 
of how the regulatory effect of physical DNA-TF inter-
actions can be examined in C. elegans is the generation of 
trans  genic animals that express green fluorescent protein 
(GFP) under the control of the DNA fragment with which 
the physical interaction was detected, and subjection of 
these transgenic animals to RNAi of the relevant TF or 
crossing  them  into  TF  mutant  animals  [19,20,36].  An 
increase in GFP expression following reduction of the TF 
would  indicate  that  the  TF  represses  gene  expression, 
whereas  a  decrease  in  GFP  expression  following  TF 
reduc  tion  would  indicate  that  the  TF  is  an  activator. 
Other methods used to determine target gene expression 
in  mutant/RNAi  animals  include  quantitative  RT-PCR 
and expression profiling (for example, [17,37]).
The final level is observing that a TF and its target share 
functional roles in a biological process, or confer similar 
phenotypes  when  mutated  and/or  overexpressed.  Such 
functional similarities can be uncovered by performing 
phenotypic  experiments,  or  alternatively,  correlations 
between  functions  can  be  investigated  in  silico  using 
Gene Ontology [38] and KEGG databases [39]. It is likely 
that a complete correlation between a TF and its target 
genes in either a biological process or a phenotype occurs 
only in a minority of cases because networks are highly 
interconnected,  and  TFs  often  have  multiple  functions 
according  to  developmental,  physiological  or  environ-
mental circumstances.
Limitations of DNA-TF validation: detection limits 
and interpretation
It is important to note that validation experiments are 
each subject to their own limitations and that a negative 
result  need  not  invalidate  the  original  interaction  ob-
served.  For  instance,  when  RNAi  is  used  to  examine 
regulatory relationships between a gene and its putative 
regulators,  off-target  effects  can  complicate  the  inter-
pretation. Therefore, it is desirable to observe the same 
effect on target gene expression with multiple small inter-
fering RNAs (siRNAs) designed to target the same regu-
lator. In C. elegans, not every tissue is equally amenable 
to RNAi; for instance, most neurons are largely refractory, 
and  interactions  occurring  there  would  wrongly  be 
deemed not valid when analyzed by RNAi [40,41]. When 
validating Y1H interactions by ChIP, it is important to 
perform  the  experiment  using  samples  that  not  only 
express  the  TF  of  interest,  but  also  under  conditions 
where  the  TF  is  active  (Figure  1).  An  example  that 
illustrates this concept is C. elegans DAF-16, a forkhead 
TF that is located in the cytoplasm in wild-type animals 
unless they are exposed to nutritional or environmental 
stress.  In  daf-2  mutants,  however,  DAF-16  aberrantly 
translocates to the nucleus and is constitutively active, 
and  the  daf-2  mutant  background  has  therefore  been 
used to identify an initial set of DAF-16-bound regions 
[12]. Some other TFs could truly be bound to DNA sites 
in vivo, but be functionally dormant until activation by a 
ligand or signaling pathway, and regulatory effects would 
only  be  detectable  under  activation  conditions.  Prior 
knowledge of TF expression [42,43] or activity will greatly 
facilitate the design of an appropriate in vivo experiment. 
For instance, we focused on animals in the dauer stage (in 
which  their  development  is  arrested)  to  validate  inter-
actions  between  microRNA  promoters  and  DAF-3, 
whose expression greatly increases in the dauer stage and 
which  confers  a  dauer-related  phenotype  [19].  Finally, 
some TFs may affect the expression of their target genes 
in  a  tissue-specific  manner,  and  some  TFs  can  even 
function as both an activator and a repressor, depending 
on  the  circumstances.  For  instance,  using  a  transgenic 
GFP  approach,  we  found  that  the  C.  elegans  nuclear 
hormone  receptor  NHR-45  activates  the  promoter  of 
nhr-178  in  some  tissues  and  under  some  conditions, 
whereas  it  represses  it  in  other  tissues  under  other 
conditions [20]. This example highlights the complexity 
of gene regulation and the caution one should take when 
interpreting  ‘whole  animal’  validation  assays,  such  as 
quantitative RT-PCR.
Limitations of DNA-TF validation
In  the  past  few  years,  it  has  become  clear  that  many 
physical  interactions  -  for  instance,  those  identified  by 
ChIP  -  do  not  convey  a  detectable  regulatory  conse-
quence  on  their  predicted  target  genes  (for  example, 
[44,45]).  This  could  be  because  the  regulatory  conse-
quences were tested under conditions in which the TF is 
not active. Alternatively, the wrong gene could have been 
attributed to the binding event, or the loss or reduction 
of  individual  TFs  could  have  been  masked  by  TF 
combinatorics or redundancy.
Both TF redundancy and combinatorics are prevalent 
in GRNs (Figure 2). For instance, multiple TFs from the 
same  family  can  act  through  a  single  binding  site  and 
function  redundantly,  so  that  loss  of  one  TF  is  com-
pensated by another (Figure 2a). Such redundancy has 
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TF  families,  including  mammalian  ETS  proteins  that 
were studied by ChIP [46] and C. elegans FLYWCH-type 
zinc fingers that were found by Y1H assays [36]. Loss of a 
TF can also be masked by combinatorics involving TFs 
from the same family (Figure 2b) or different (Figure 2c) 
families, in which each TF contributes only a small regu-
latory effect, and this can lead to apparent redundancy. 
Such built-in redundancy may be very useful for critical 
genes  that  need  to  be  buffered  to  avoid  detrimental 
phenotypic consequences of TF loss [47].
Physical interactions between TFs and genomic DNA 
fragments are often inferred to affect the gene that is in 
closest linear proximity to the binding event. For inter-
actions that occur close to a transcription start site, either 
in a gene promoter or just downstream in the transcribed 
region,  this  is  a  reasonable  assumption.  Interactions 
involving  more  distant  DNA  elements  (such  as 
enhancers), however, may not necessarily affect a nearby 
gene  because  the  genome  is  not  organized  as  a  linear 
polymer, but rather is organized in three dimensions [48]. 
Studies  using  chromatin  conformation  capture  tech-
niques  [49]  are  providing  insights  into  which  genomic 
regions contact each other to form loops, potentially to 
bring  together  enhancers  and  gene  promoters.  Inte-
grating  physical  and  regulatory  interaction  data  with 
structural genome and DNA looping data will facilitate 
the further dissection of GRNs.
Conclusions
When is an interaction between a genomic DNA frag-
ment and a TF biologically meaningful? When the gene 
located  closest  to  the  binding  event  changes  in 
expression following loss or reduction of the TF? When 
Figure 2. The regulatory effect of a TF on a target gene can be masked when the TF is mutated (loss of function) or when its levels are 
reduced by RNAi. Two mechanisms that explain such masking are (a) TF redundancy and (b,c) the combinatorial interactions between multiple 
TFs, either from (b) one family or (c) from different families. In any of these cases, loss of a single TF would have only modest effects on target gene 
expression. Similar shapes with different colors indicate members of the same TF family; different shapes indicate members of different TF families.
Wild type √ TF mutant/RNAi
(a) TF redundancy: one TF family member can buffer the loss of another
(b) TF combinatorics: multiple members of a family regulate a gene, and loss of only one has little effect
(c) TF combinatorics: different types of TF regulate a gene, and loss of a single TF has little effect
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the  answers  are  not  simple,  and  the  assays  used  to 
validate interactions are not foolproof. However, when 
the methods used for GRN delineation are robust and 
technically sound, individual interactions should not be 
discarded when one or more validation methods fail to 
detect  regulatory  or  phenotypic  consequences, 
particularly  in  complex,  whole  organisms.  Rather, 
multiple methods need to be com  bined into increasingly 
integrated  networks  to  attribute  different  degrees  of 
confidence to each of the interactions observed.
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